IFLR1000

Bain and Cinven €5.3 billion takeover of Stada

22/8/2017
Leveraged finance, Public acquisition
Select tab

€ 5.3 billion

$ 6.34 billion

Announced

22/8/2017

Overview:

  • Private equity houses Bain and Cinven have reached an agreement to takeover Stada for €5.3 billion including debt.
  • The offer for Stada, a German generic pharmaceutical manufacturer, equates to €66.25 per share. 
  • Earlier in 2017, Bain and Cinven failed in a first bid to takeover Stada after not securing the necessary approval threshold from shareholders.
  • The deal is subject to regulatory approval. 

Katrin Kostadinova - Data analyst 

Jurisdiction:

Germany

Deal types:

Leveraged finance
Public acquisition

Practice areas:

Banking
Private equity
M&A

Governing law:

Germany

Industry sector:

Pharmaceuticals and life sciences

Firms:
Freshfields Bruckhaus Deringer

Party: Stada ArzneimittVna ON (Target)

Lawyers: Christoph Seibt, Natascha Doll

Kirkland & Ellis

Party: Bain Capital (Acquirer)

Party: Cinven (Acquirer)

Lawyers: Achim Herfs, Anna Schwander, Benjamin Leyendecker, Christopher Shield, Daniel Borg, Stephen Lucas, Wolfgang Nardi

Latham & Watkins

Party: Lenders (Lenders)

Lawyers: Alexander Lentz, Alexandra Hagelüken, Oliver Seiler, Sibylle Münch, Stephen Kensell

Skadden Arps Slate Meagher & Flom

Party: Stada's supervisory board (Target)

Lawyer: Bernd R Mayer

Related deals